A simple and sensitive high-performance liquid chromatographic method for the determination of vinflunine and 4-O-deacetylvinflunine from human blood

Therapeutic Drug Monitoring

Volumn 32, Issue 6, 2010, Pages 734-740

  Zorza, Grégoire ^a   Pellerin, Delphine ^b   Fortune, Valérie ^b   Puozzo, Christian ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b Mediscis Laboratories   (France)

Author keywords

4 O deacetylvinflunine; blood; human; liquid chromatography; vinflunine

Indexed keywords

4 O DEACETYLVINFLUNINE; DRUG METABOLITE; UNCLASSIFIED DRUG; VINFLUNINE;

ANALYTIC METHOD; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; REPRODUCIBILITY; ULTRAVIOLET RADIATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET; VINBLASTINE;

EID: 78650299383     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181f6010c     Document Type: Article

References (26)

1. Jacquesy JC, Fahy J. Cancer: superacid generation of new antitumor agents. In: Biomedical Chemistry: Applying chemical principles to the understanding and treatment of disease. New York: Wiley-Interscience; 2000:227-246.
2. Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol. 2001;40:159-173.
3. Kruczynski A, Poli M, Dossi R, et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer. 2006;42:2821-2832.
4. Souquet PJ, Krzakowski M, Ramlau R, et al. Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with adVanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11:105-113.
5. Bennouna J, Delord JP, Campone M, et al. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res. 2008;14:1625-1632.
6. Bennouna J, Campone M, Delord JP, et al. Vinflunine: a novel antitubulin agent in solid malignancies. Expert Opin Investig Drugs. 2005;14:1259-1267.
7. Yun-San Yip A, Yuen-Yuen Ong E, Chow LW. Vinflunine: clinical perspectives of an emerging anticancer agent. Expert Opin Investig Drugs. 2008;17:583-591.
8. Lobert S, Puozzo C. Pharmacokinetics, metabolites, and preclinical safety of vinflunine. Semin Oncol. 2008;35:S28-S33.
9. Nicot G, Lachatre G, Marquet P, et al. High-performance liquid chromatographic determination of navelbine in human plasma and urine. J Chromatogr. 1990;528:258-266.
10. Van Tellingen O, Kuijpers A, Beijnen JH, et al. Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1992;573:328-332.
11. Ragot S, Sauvage FL, Rousseau A, et al. Sensitive determination of vinorelbine and its metabolites in human serum using liquid chromatog-raphy- electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl. 2001;753:167-178.
12. Puozzo C, Ung HL, Zorza G. A high performance liquid chromatog-raphy method for vinorelbine and 4-O-deacetyl vinorelbine: a decade of routine analysis in human blood. J Pharm Biomed Anal. 2007;44: 144-149.
13. Kobayashi S, Sakai T, Dalrymple PD, et al. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. Arzneimittelforschung. 1993;43: 1367-1377.
14. Robieux I, Vitali V, Aita P, et al. Sensitive high-performance liquid chromatographic method with fluorescence detection for measurement of vinorelbine plasma concentrations. J Chromatogr B Biomed Appl. 1996; 675:183-187.
15. Urien S, Bree F, Breillout F, et al. Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemother Pharmacol. 1993;32:231-234.
16. Bree F, Blanchot G, Tillement JP, et al. In vitro distribution of [3H]-vinflunine in human blood. Binding to platelets and serum proteins. Proc Ann Meeting Am Assoc Cancer Res. 2002;43:Abstract 1047.
17. Van Tellingen O, Beijnen JH, Nooyen WJ. Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature. J Pharm Biomed Anal. 1991;9:1077-1082.
18. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry: Bioanalytical Methods Validation. Rockville, MD: Food and Drug Administration, 2001.
19. Lobert S, Fahy J, Hill BT, et al. Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line. Biochemistry. 2000;39:12053-12062.
20. EtieVant C, Barret JM, Kruczynski A, et al. Vinflunine (20',20'-difluoro-3'4'-dihydrovinorelbine), a novel vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs. 1998;16:3-17.
21. Zorza G, Van Heugen JC, de Graeve J, et al. Development of a sensitive liquid chromatography method coupled with a tandem mass spectrometric detection for the clinical analysis of vinflunine and 4-O-deacetyl vinflunine in blood, urine and faeces. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853:294-302.
22. Focan C, Van Heugen JC, Kreutz F, et al. Vinflunine metabolism and disposition in cancer patients. Proc Ann Meeting Am Soc Clin Oncol. 2002;21:Abstract 421a.
23. Lang JR Bolton S. A comprehensive method validation strategy for bioanalytical applications in the pharmaceutical industry-1. Experimental considerations. J Pharm Biomed Anal. 1991;9:357-361.
24. Rocci ML Jr, DeVanarayan V, Haughey DB, et al. Confirmatory reanalysis of incurred bioanalytical samples. AAPS J. 2007;9:E336-E343.
25. Viswanathan CT, Bansan S, Booth B, et al. Workshop/Conference report quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand assays. AAPS J. 2007;9:E30-E42.
26. Nguyen L, Retout S, Mentre F, et al. Population pharmacokinetics of vinflunine from phase I data and evaluation of population sampling designs for further clinical development. Proc Ann Meeting Population Approach Group in Europe. 2002:Abstract 11.